You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH):與北京恩瑞尼設合資公司 主要從事CD39藥物的研發、 臨牀應用及商業化發展
格隆匯 09-09 18:16

格隆匯 9 月 9日丨君實生物(688180.SH)公佈,近日,公司與北京恩瑞尼生物科技股份有限公司(“北京恩瑞尼”)就成立合資公司訂立股東合作協議。合資公司將主要從事CD39藥物的研發、 臨牀應用及商業化發展。在其成立後,合資公司將分別由公司及北京恩瑞尼擁有50%及50%的權益。

北京恩瑞尼將向合資公司作出非現金注資,即透過合資公司轉讓其在中國地區(包括中國香港特別行政區、中國澳門特別行政區及台灣地區)的CD39藥物的所有知識產權及開發及銷售權的方式。公司將向合資公司通過現金注資。

合資公司將分別由公司及北京恩瑞尼分別擁有50%及50%的權益。合資公司將主要從事CD39藥物的研發、臨牀應用及商業化發展。CD39項目直接或間接產生的利益(透過股份買賣、藥物授權、藥物銷售、技術轉移等任何方式進行及經扣除成本,包括製造及銷售成本)將按訂約方各自於合資公司的股權比例分派予訂約方。

CD39為負責在腫瘤微環境中將免疫刺激性細胞外ATP轉化為免疫抑制腺苷(ADO)的初始步驟的酶,並在腫瘤微環境免疫抑制反應中扮演着重要角色。研究表明,CD39在各種人類腫瘤中均呈現高表達現象,包括淋巴瘤、肉瘤、肺癌、胰腺癌、卵巢癌、腎細胞癌、甲狀腺癌和睾丸癌等。根據公開資料,全球範圍內,目前有至少3款CD39靶向藥物進入臨牀試驗。該項目的CD39產品擁有獨特創新的設計理念,通過選擇性地靶向腫瘤微環境中高表達CD39的免疫抑制性細胞從而來實現高藥效的同時,降低潛在的系統性副作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account